Stock DNA
Pharmaceuticals & Biotechnology
SEK 199 Million (Micro Cap)
NA (Loss Making)
NA
0.00%
0.08
879.64%
-51.09
Revenue and Profits:
Net Sales:
(Quarterly Results - Dec 2025)
Net Profit:
-8 Million
Total Returns (Price + Dividend) 
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
28.2%
0%
28.2%
6 Months
50.97%
0%
50.97%
1 Year
-38.05%
0%
-38.05%
2 Years
158.77%
0%
158.77%
3 Years
12.83%
0%
12.83%
4 Years
-84.91%
0%
-84.91%
5 Years
-89.03%
0%
-89.03%
Klaria Pharma Holding AB for the last several years.
Risk Adjusted Returns v/s 
News
No Recent News for the Company
Announcements 
No announcement available
Corporate Actions 
No corporate action available
Quality key factors 
Factor
Value
Sales Growth (5y)
58.46%
EBIT Growth (5y)
9.00%
EBIT to Interest (avg)
-10.64
Debt to EBITDA (avg)
Negative Net Debt
Net Debt to Equity (avg)
-0.90
Sales to Capital Employed (avg)
0.65
Tax Ratio
0
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
0
ROCE (avg)
0
ROE (avg)
0
Valuation key factors
Factor
Value
P/E Ratio
NA (Loss Making)
Industry P/E
Price to Book Value
-6.54
EV to EBIT
-4.66
EV to EBITDA
-8.41
EV to Capital Employed
-5.81
EV to Sales
11.77
PEG Ratio
NA
Dividend Yield
NA
ROCE (Latest)
Negative Capital Employed
ROE (Latest)
Negative BV
Technicals key factors
Indicator
Weekly
Monthly
MACD
Mildly Bearish
Mildly Bullish
RSI
No Signal
No Signal
Bollinger Bands
Sideways
Mildly Bullish
Moving Averages
Mildly Bullish (Daily)
KST
Mildly Bearish
Mildly Bearish
Dow Theory
No Trend
No Trend
OBV
Mildly Bearish
Mildly Bullish
Shareholding Snapshot
No data for shareholding present.
Shareholding Compare (%holding) 
No data for shareholding present.
Quarterly Results Snapshot (Consolidated) - Dec'25 - QoQ
Dec'25
Sep'25
Change(%)
Net Sales
0.00
0.00
Operating Profit (PBDIT) excl Other Income
-7.00
-2.60
-169.23%
Interest
1.40
2.10
-33.33%
Exceptional Items
0.00
0.00
Consolidate Net Profit
-8.40
-8.70
3.45%
Operating Profit Margin (Excl OI)
0.00%
0.00%
NA
USD in Million.
Net Sales
QoQ Growth in quarter ended Dec 2025 is 0.00% vs 0.00% in Sep 2025
Consolidated Net Profit
QoQ Growth in quarter ended Dec 2025 is 3.45% vs 56.72% in Sep 2025
Annual Results Snapshot (Consolidated) - Dec'25
Dec'25
Dec'24
Change(%)
Net Sales
9.00
2.20
309.09%
Operating Profit (PBDIT) excl Other Income
-14.00
-20.10
30.35%
Interest
13.70
16.40
-16.46%
Exceptional Items
0.00
0.00
Consolidate Net Profit
-38.90
-47.80
18.62%
Operating Profit Margin (Excl OI)
-2,808.80%
-13,916.80%
1,110.80%
USD in Million.
Net Sales
YoY Growth in year ended Dec 2025 is 309.09% vs -74.12% in Dec 2024
Consolidated Net Profit
YoY Growth in year ended Dec 2025 is 18.62% vs -33.52% in Dec 2024
About Klaria Pharma Holding AB 
Klaria Pharma Holding AB
Pharmaceuticals & Biotechnology
Klaria Pharma Holding AB (publ) is a Sweden-based holding company engaged in the biotechnology and medical research industry. Through its group subsidiaries, the Company is active in developing and commercializing therapeutic drugs and treatment methods in the fields of migraine and pain related to cancer based on a patented drug delivery platform in the form of an alginate-based polymer film, which facilitates rapid and reliable transmucosal absorption via a muco-adhesive film. The Company operates Klaria Pharma AB as a wholly owned subsidiary.
Company Coordinates 
Company Details
Virdings Alle 2 , UPPSALA None : 754 50
Registrar Details






